What is Attralus?
Headquartered in San Francisco, California, Attralus is dedicated to advancing treatments for systemic amyloidosis, a rare and progressive disease. The company's focus on this challenging condition positions it within a specialized segment of the biopharmaceutical industry. Its strategic financing rounds, including a Series B in September 2021 and a Series A in September 2020, indicate a trajectory of scaling operations and advancing its research and development initiatives. The substantial capital raised suggests a commitment to significant clinical and pre-clinical advancements.
How much funding has Attralus raised?
Attralus has raised a total of $141M across 2 funding rounds:
Series A
$25M
Series B
$116M
Series A (2020): $25M with participation from venBio Partners
Series B (2021): $116M led by Janus Henderson Investors, Logos Capital, Redmile Group, and Samsara BioCapital
Key Investors in Attralus
Janus Henderson Investors
Janus Henderson Investors, a global asset management firm with a long history, likely provides strategic financial backing and market expertise to Attralus, supporting its growth in the biopharmaceutical sector.
Logos Capital
Logos Capital, operating in the venture capital space, is expected to contribute significant investment and strategic guidance to Attralus, focusing on its development and commercialization efforts.
venBio Partners
venBio Partners, a life sciences investment firm, brings specialized expertise in developing innovative medicines, likely supporting Attralus's pipeline advancement and strategic partnerships in the biopharmaceutical industry.
What's next for Attralus?
With the recent infusion of major strategic investment, Attralus is poised for accelerated growth and the expansion of its therapeutic programs. The company's ability to attract significant backing from established investors highlights the perceived value and potential impact of its work in systemic amyloidosis. Future endeavors will likely involve advancing its drug candidates through clinical trials, potentially expanding its research into related conditions, and further solidifying its position as a key player in the rare disease therapeutic landscape. This sustained financial backing is crucial for navigating the lengthy and capital-intensive drug development process.
See full Attralus company page
